Company: MBIO
Filing Date: 2025-07-09
Form Type: 8-K
Source: 0001104659-25-066520
Chunk: 0

Company: MUSTANG BIO, INC.
Filing Date: 2025-07-09
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01.      Other Events.  

On July
7, 2025, Mustang Bio, Inc. (the “ Company” or “ Mustang”) issued a press release to announce that the U. S. Food
and Drug Administration has granted Orphan Drug Designation to the Company for MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment
of recurrent diffuse and anaplastic astrocytoma (astrocytomas) and glioblastoma (GBM). A copy of the press release is filed herewith as
Exhibit 99.1 to this report and is incorporated herein by reference.